Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes
OPEN Annals of oncology : official journal of the European Society for Medical Oncology / ESMO | 26 Feb 2015
CY Cheah, D Chihara, JE Romaguera, NH Fowler, JF Seymour, FB Hagemeister, RE Champlin and ML Wang
Abstract
Although ibrutinib is highly effective in patients with relapsed/refractory mantle cell lymphoma (MCL), a substantial proportion of patients have resistant disease. The subsequent outcomes of such patients are unknown.
- Tweets*
- 15
- Facebook likes*
- 0
- Reddit*
- 0
- News coverage*
- 1
- Blogs*
- 0
- SC clicks
- 4
- Concepts
- Mantle zone, Lymphoma, Chemotherapy, Cancer, Mantle cell lymphoma
- MeSH headings
- -
comments powered by Disqus
* Data courtesy of Altmetric.com